Omnicell (OMCL) Q4 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2023 earnings summary
7 Nov, 2026Executive summary
FY2023 revenue was $1.147B, down 11% YoY; Q4 revenue was $259M, down 13% YoY.
Advanced Services revenue grew 14% to $213M, reaching 19% of FY revenue; FY2024 target is 21%.
FY2024 guidance: revenue of $1.045B–$1.120B and non-GAAP EBITDA of $90M–$120M.
Management plans a holistic business review to optimize investment and accelerate profitability.
Financial highlights
Q4 non-GAAP gross margin was 43.6%, down 170 bps YoY; non-GAAP operating expenses were $103M, down 17%.
Q4 non-GAAP EBITDA was $24M versus $26M YoY; diluted non-GAAP EPS was $0.33, unchanged YoY.
FY2023 non-GAAP EBITDA was $137.9M versus $192.9M; non-GAAP diluted EPS was $1.91 versus $3.00.
FY2023 GAAP net loss was $20.4M, versus net income of $5.6M in FY2022; non-GAAP net income was $87M.
Lower Point of Care revenue reflected healthcare systems’ capital budget and labor constraints.
Outlook and guidance
FY2024 revenue guidance is $1.045B–$1.120B; product revenue $605M–$650M and service revenue $440M–$470M.
FY2024 technical services and Advanced Services revenue are each guided to $220M–$235M; Advanced Services target is 21% of total revenue.
FY2024 bookings guidance is $750M–$875M; non-GAAP EBITDA is $90M–$120M and non-GAAP EPS is $0.90–$1.40.
Q1 2024 revenue guidance is $232M–$242M; non-GAAP EBITDA is $(2)M–$4M and non-GAAP EPS is $(0.10)–$0.00.
Free cash flow is expected to slow as investment continues in the transition to Advanced Services.
Latest events from Omnicell
- Q3 profitability beat guidance; FY EBITDA and EPS outlook increased amid back-end-weighted bookings.OMCL
Q3 2026 - Titan XT and OmniSphere drive a flexible, customer-focused refresh cycle with strong financial discipline.OMCL
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue rose 7% to $312M, with higher margins and a $14M–$15M tariff refund.OMCL
Q2 2026 - Growth accelerates with new cloud-based products, AI integration, and a focus on recurring revenue.OMCL
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Titan XT and OmniSphere launch drive a pivotal product cycle and margin-focused strategy.OMCL
Bank of America Global Healthcare Conference 2026 - Q1 2026 saw 15% revenue growth, margin gains, and raised profit guidance.OMCL
Q1 2026 - 2026 meeting seeks approval for director elections, pay, equity plan, officer exculpation, and auditor.OMCL
Proxy filing - Proxy seeks approval on director elections, compensation, equity plan, officer exculpation, and auditor.OMCL
Proxy filing - Q3 revenue fell 5% to $282M, net income rose, and 2024 guidance for EBITDA and EPS increased.OMCL
Q3 2024